Bio Usawa Appoints New Leader in Global Regulatory Strategy

In a significant move poised to bolster healthcare across Africa, Bio Usawa, Inc., the burgeoning biotech company renowned for its commitment to making monoclonal antibody therapies accessible and affordable, has announced the appointment of Mr. Eric Karikari-Boateng as the Head of Global Regulatory Strategy. This strategic hiring could pave the way for revolutionary advances in the regulation and delivery of life-saving therapies on the continent.

Mr. Karikari-Boateng's Expertise

Mr. Karikari-Boateng, an acclaimed expert in regulatory affairs, holds a wealth of experience in pharmaceutical manufacturing and quality assurance. His impressive resume includes a tenure as Director of Laboratories at the Ghana Food and Drug Authority, where he was instrumental in the regulatory approval of significant medical innovations, including the groundbreaking R21 malaria vaccine—an achievement that made Ghana the first nation to grant approval for this life-saving treatment.

Leadership in Regulatory Affairs

As a recognized leader in various regulatory platforms, he has engaged with the African Medicines Regulatory Harmonization initiative and chairs the Biologics Regulation Forum within the African Vaccine Regulation Forum. His collaboration with esteemed organizations like the World Health Organization and the European Medicines Agency further highlights his pivotal role in evaluating innovative products, such as the RTS,S malaria vaccine and Pyramax, a combination treatment for malaria.

Commitment to Training and Development

With his certification as a cGMP inspector from the American Society for Quality and experience as a lead trainer in Good Clinical Practice, Mr. Karikari-Boateng has enriched the skills of numerous regulators across Africa, improving their capabilities in assessing biologics and clinical trial data. His new role at Bio Usawa is seen as a critical step towards ensuring that innovative treatments can be delivered to those in need swiftly and efficiently.

Praise from Leadership

Dr. Patrick Lukulay, Chief Regulatory Officer at Bio Usawa, praised Mr. Karikari-Boateng’s unmatched expertise and commitment to public health, stating, "His vision and regulatory knowledge will be vital in our mission to elevate healthcare standards and ensure timely access to transformative therapies."

Bio Usawa's Mission

Bio Usawa, headquartered in Rwanda, is at the forefront of producing affordable monoclonal antibodies targeting cancer, autoimmune diseases, and infectious diseases. With partnerships and innovations, the company is dedicated to reshaping healthcare access in Africa, and with leaders like Mr. Karikari-Boateng at the helm of global regulatory strategy, the future looks promising.

Stay Updated

Stay tuned for updates as Bio Usawa continues its mission to revolutionize healthcare across the continent!